Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Seres Therapeutics (MCRB) Interest & Investment Income: 2016-2025

Historic Interest & Investment Income for Seres Therapeutics (MCRB) over the last 10 years, with Sep 2025 value amounting to $618,000.

  • Seres Therapeutics' Interest & Investment Income fell 5.21% to $618,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year decrease of 59.66%. This contributed to the annual value of $4.0 million for FY2024, which is 45.66% down from last year.
  • According to the latest figures from Q3 2025, Seres Therapeutics' Interest & Investment Income is $618,000, which was up 13.19% from $546,000 recorded in Q2 2025.
  • Over the past 5 years, Seres Therapeutics' Interest & Investment Income peaked at $2.6 million during Q3 2023, and registered a low of $384,000 during Q1 2022.
  • For the 3-year period, Seres Therapeutics' Interest & Investment Income averaged around $1.2 million, with its median value being $1.0 million (2023).
  • As far as peak fluctuations go, Seres Therapeutics' Interest & Investment Income surged by 1,020.27% in 2021, and later slumped by 77.83% in 2024.
  • Quarterly analysis of 5 years shows Seres Therapeutics' Interest & Investment Income stood at $485,000 in 2021, then surged by 191.55% to $1.4 million in 2022, then surged by 39.39% to $2.0 million in 2023, then slumped by 77.83% to $437,000 in 2024, then declined by 5.21% to $618,000 in 2025.
  • Its last three reported values are $618,000 in Q3 2025, $546,000 for Q2 2025, and $618,000 during Q1 2025.